Press release
Thyroid Carcinoma Disease Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018
Thyroid Carcinoma Disease Pipeline Drugs
Overview:
Thyroid Carcinomais the most common malignant tumor of endocrine system. Most frequent type of thyroid malignancy is papillary carcinoma. These tumors frequently have genetic alterations leading to activation of mitogen-activated protein kinase (MAPK) signaling pathway. Thyroid carcinoma manifests as a palpable, painless solitary thyroid nodule. Symptoms associated with thyroid carcinoma are solitary nodules, hard and fixed nodules, neck pain, cough, breathing problem, trouble swallowing, voice changes etc.
Thyroid carcinoma diagnosis includes blood test, fine needle aspiration biopsy, CT scan, Ultrasonography, MRI, Indirect laryngoscopy, PET Scan, Nuclear medicine scan etc. Generally, treatment of thyroid cancers includes chemotherapy, hormone therapy, radiation therapy, surgery, targeted therapy.
A sample of this report is available upon request @
https://www.precisionbusinessinsights.com/market-reports/thyroid-carcinomadisease-pipeline-drugs-assessment/#ulp-4H8Z4LpNMLEuOnnx
Segmentation:
By Trial Phase, Thyroid Carcinoma pipeline drugs are segmented as:
• Preclinical Trials
• Phase 1
• Phase 2
• Phase 3
• Phase 4
By Company, Thyroid Carcinoma pipeline drugs are segmented as:
• Eisai Inc.
• Pfizer
• Astra Zeneca
• GlaxoSmithKline
• Novartis Pharmaceuticals
• Bayer
• Sanofi
• Celldex Therapeutics
• Genentech, Inc.
• Others
By Drugs, Thyroid Carcinoma pipeline drugs are segmented as:
• Pembrolizumab
• Nivolumab
• Sorafenib
• Sulfatinib
• Anlotinib
• Nab-paclitaxel
• Pazopanib Hydrochloride
• Others
By Types of Thyroid Cancer, Thyroid Carcinoma pipeline drugs are segmented as:
• Papillary Carcinoma
• Follicular Carcinoma
• Hurthle Cell Carcinoma
• Medullary Thyroid Carcinoma
• Anaplastic Carcinoma
By Route of Administration, Thyroid Carcinoma pipeline drugs are segmented as:
• Oral
• Parenteral
To view TOC of this report is available upon request @
https://www.precisionbusinessinsights.com/market-reports/thyroid-carcinomadisease-pipeline-drugs-assessment/#ulp-c654SbFYO64MsOhu
Space Analysis:
• In March 2017, CSPC ZhongQi Pharmaceutical Technology Co., Ltd. commenced an open Label Phase Ⅱ Clinical Trial of Doxorubicin Hydrochloride Liposome Injection Combined With Cisplatin in the Treatment of Advanced Poorly Differentiated Thyroid Carcinoma
• In November 2015, Kolltan Pharmaceuticals, Inc., presented pre-clinical findings which determines that Company’s KTN3379 reverses ErbB3-mediated resistance of BARF and MEK inhibitors in BRAF-mutated thyroid cancer and melanoma. Based on these pre-clinical findings support Kolltan’s ongoing Phase 1b clinical trials in BRAF-mutant tumors and the recently initiated clinical trial in thyroid cancer. In November 2016, Celldex Therapeutics, Inc. acquired Kolltan Pharmaceuticals. Kolltens KTN3379 has changed to CDX_3379.
Report Description:
Thyroid Carcinoma Disease Pipeline Drugs Assessment report studies the various therapeutics under clinical development for Thyroid Carcinoma treatment along with targets for various drug candidate. The report provides plethora of information pertaining to trail phases, companies involved in the Thyroid Carcinoma disease pipeline drugs development. This report studies the dynamics of the Thyroid Carcinoma Disease Pipeline Drugs i.e. drivers, challenges and opportunities which are significantly impacting the product development. The report provides various information pertaining the clinical trials such as designation, grants, patents, and technology among others. Moreover, the report on Thyroid Carcinoma disease pipeline drugs assessment comprehensively presents the geographic location, trial status information along with key players involved in the therapeutics development.
Need more information about this report @
https://www.precisionbusinessinsights.com/market-reports/thyroid-carcinomadisease-pipeline-drugs-assessment/#ulp-14mlyhjMGhVjZqa3
Key Features of the Report:
• Provides the information related to universities and research institutes working in the therapeutics development
• Report comprehensively covers the all active and discontinued studies
• Studies the entire pipeline with special emphasis on companies actively involved in the therapeutics development
• Presents the prominent targets for drug development in each stage of clinical trial
• Provides the in-depth analysis on the each drug candidates in the clinical trial phases
Get access to full summary @
https://www.precisionbusinessinsights.com/market-reports/thyroid-carcinomadisease-pipeline-drugs-assessment/
About Precision Business Insights
Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customised market research services based on our client needs.
Contact to Precision Business Insights,
Kemp House,
152 – 160 City Road,
London EC1V 2NX
Email: sales@precisionbusinessinsights.com
Toll Free (US): +1-866-598-1553
Website @ https://www.precisionbusinessinsights.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Thyroid Carcinoma Disease Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018 here
News-ID: 1052059 • Views: …
More Releases from Precision Business Insights
Gaming Controller Market Rising Demand for Gaming Stations and eSports
According to the Precision Business Insights (PBI), latest report the gaming controller market size was valued at USD 2,382.1 million in 2023, growing at an 8.5% CAGR from 2024 to 2030. The key drivers of the expansion of the global gaming controller include the enhanced gaming experience, technology advancements, consumer preferences and ergonomics, competitive gaming and esports, intuitiveness, and portability of the gaming controllers.
View Full Report: https://www.precisionbusinessinsights.com/market-reports/gaming-controller-market …
Next Generation Dietary Supplements Market Size, Growth Opportunities 2024-2030
According to Precision Business Insights (PBI), the latest report, the global next-generation dietary supplements market was valued at USD 10,752.3 million in 2023 and is expected to grow at a CAGR of 8.8% from 2024-2030. The primary factors that drive the market are the growing demand for rising consumer knowledge of the various health benefits of Next Generation Dietary Supplements, as well as rising disposable income levels, fuel market expansion…
Catamaran Market Increasing Popularity Of Water Sports And Fishing Activities
According to Precision Business Insights (PBI), the latest report, the catamaran market is valued at USD 1,635.7 million in 2023 and is anticipated to grow a CAGR of 4.9% over the forecast period. The primary factors that drive the market are the growing demand for Catamaran pushes the market to enhance efficiency, minimize time consumption, and reduce post-harvest operating losses. Catamaran are good solutions for reducing high labour costs since…
Refrigerated Display Cases Market Size, Share, Growth Trends and Forecast 2024-2 …
According to Precision Business Insights (PBI), latest report, the refrigerated display cases market was valued at USD 8,248.5 million in 2023 and is expected to grow at a 5.1% CAGR from 2024 to 2030. The primary drivers of the expansion of the global refrigerated display cases market include the increasing demand for frozen food and drinks among urban consumers. In addition, growing awareness about environment sustainability and energy efficiency is…
More Releases for Carcinoma
Rising Occurrence Of Hepatocellular Carcinoma Fuels Growth In The Hepatocellular …
The Hepatocellular Carcinoma Drugs Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Hepatocellular Carcinoma Drugs Market Size During the Forecast Period?
The Hepatocellular Carcinoma Drugs Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025…
Major Market Shift in Urothelial Carcinoma Treatment Industry: Innovations In Ur …
What Is the Forecasted Market Size and Growth Rate for the Urothelial Carcinoma Treatment Market?
In the recent years, there has been a swift escalation in the size of the urothelial carcinoma treatment market. It is projected to expand from $2.86 billion in 2024 to $3.37 billion in 2025, boasting a Compound Annual Growth Rate (CAGR) of 18.0%. The growth during the past period can be credited to an upsurge in…
Hepatocellular Carcinoma Pipeline 2024
DelveInsight, "Hepatocellular Carcinoma Pipeline Insight 2024" report provides comprehensive insights about 90+ companies and 95+ pipeline drugs in Hepatocellular Carcinoma pipeline landscape. It covers the Hepatocellular Carcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hepatocellular Carcinoma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Request a sample and discover the recent…
Urothelial Carcinoma Pipeline Outlook Report 2024 (Updated)
DelveInsight's, "Urothelial Carcinoma Pipeline Insight 2024" report provides comprehensive insights about 40+ Urothelial Carcinoma companies and 50+ pipeline drugs in the Urothelial Carcinoma pipeline landscape. It covers the Urothelial Carcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Urothelial Carcinoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways…
Urothelial Carcinoma Pipeline Insights Report 2024
DelveInsight's, "Urothelial Carcinoma Pipeline Insight 2024" report provides comprehensive insights about 40+ Urothelial Carcinoma companies and 50+ pipeline drugs in the Urothelial Carcinoma pipeline landscape. It covers the Urothelial Carcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Urothelial Carcinoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways…
Nasopharyngeal Carcinoma Treatment Market
The latest Report Available at USD Analytics Market, "Nasopharyngeal Carcinoma Treatment Market" provides a pin-point analysis of changing competitive dynamics and a forward-looking perspective on different factors driving or restraining industry growth.
As the Political, Economic, Social, Technological, Environmental, and Legal factors continue to change, business leaders across industries have shifted focus to strategic objectives to achieve market excellence. The "Global Nasopharyngeal Carcinoma Treatment Market Size, Share Analysis with Forecast to…
